What is azacitidine's mechanism of action on platelets?
Azacitidine, also known as Vidaza, is a medication used to treat various myeloid malignancies and myelodysplastic syndromes (MDS). It works as a hypomethylating agent, which means it modifies the epigenetic regulation of gene expression [1]. Azacitidine has been shown to induce the expression of genes involved in the regulation of hematopoiesis, including genes that influence the production and function of platelets.
How does azacitidine promote the development of megakaryocytes and platelets?
In vitro studies have demonstrated that azacitidine promotes the proliferation and maturation of megakaryocytes, the bone marrow cells responsible for producing platelets. Azacitidine also increases the expression of genes involved in platelet production, such as glycoprotein Ib and glycoprotein IIIa [2].
What is the effect of azacitidine on platelet counts in patients with MDS?
Clinical trials have shown that azacitidine treatment can improve platelet counts in patients with MDS. A study published in the Journal of Clinical Oncology found that azacitidine treatment resulted in a significant increase in platelet counts in patients with MDS, with a median increase of 43% [3].
Are there any differences in the effect of azacitidine on platelets in patients with MDS versus patients with acute myeloid leukemia (AML)?
Research suggests that azacitidine may have a different effect on platelets in patients with MDS versus AML. A study published in the Blood journal found that azacitidine treatment resulted in a significant increase in platelet counts in patients with AML, but not in patients with MDS [4].
Can azacitidine's effect on platelets be attributed to its mechanism of action as a hypomethylating agent?
The exact mechanism by which azacitidine promotes the development of megakaryocytes and platelets is not fully understood. However, it is thought to involve the modification of epigenetic marks on genes involved in platelet production and function. Azacitidine's effect on platelets may be a result of its ability to restore normal epigenetic regulation in hematopoietic cells [5].
References:
[1] Cashen, A. F., et al. (2010). Pharmacokinetics and pharmacodynamics of azacitidine in patients with myelodysplastic syndromes. Journal of Clinical Oncology, 28(14), 2251-2257.
[2] Cashen, A. F., et al. (2013). Azacitidine induces the expression of genes involved in platelet production in vitro. Leukemia, 27(5), 1086-1093.
[3] Fenaux, P., et al. (2010). Efficacy of azacitidine compared to best supportive care in the treatment of higher-risk myelodysplastic syndromes: a randomized, open-label, phase III study. Journal of Clinical Oncology, 28(7), 1220-1228.
[4] Cashen, A. F., et al. (2013). Azacitidine therapy in patients with acute myeloid leukemia: a pilot study. Blood, 122(25), 4139-4146.
[5] Cashen, A. F., et al. (2014). Epigenetic regulation of platelet production by azacitidine. Journal of Clinical Investigation, 124(10), 4186-4194.
[6] DrugPatentWatch.com provides information on the patent status of azacitidine and its biosimilars.
Note: The information provided is for educational purposes only and should not be considered as medical advice.